SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Facon, T. Articles by Mary, J.-Y. Search for Related Content PubMed PubMed Citation Articles by Facon, T. Articles by Mary, J.-Y. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 March 2001, Vol. 97, No. 6, pp. 1566-1571 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Chromosome 13 abnormalities identified by FISH analysis and serum 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy Thierry Facon, Hervé Avet-Loiseau, Gaëlle Guillerm, Philippe Moreau, Franck Geneviève, Marc Zandecki, Jean-Luc Laï, Xavier Leleu, Jean-Pierre Jouet, Francis Bauters, Jean-Luc Harousseau, Régis Bataille, and Jean-Yves Mary on behalf of the Intergroupe Francophone du Myélome (IFM) From the Service d'Hématologie and Laboratoire de Génétique Médicale, Lille, France; Service d'Hématologie and Laboratoire d'Hématologie, Nantes, France; Laboratoire d'Hématologie, Angers, France; and Equipe Biostatistiques/Biomathématiques, Université Paris VII, Paris, France.     Abstract Top Abstract Introduction Patients, materials, and... Results Discussion References A careful prognostic evaluation of patients referred for high-dose therapy (HDT) is warranted to identify those who maximally benefit from HDT as well as those who clearly fail current HDT and are candidates for more innovative treatments. In a series of 110 patients with myeloma who received HDT as first-line therapy, times to event (disease progression and death) were studied through proportional hazard models, in relation to different prognostic factors, including a chromosome 13 fluorescence in situ hybridization (FISH) analysis using a D13S319 probe. 13 was detected in 42 patients (38%). Follow-up time among surviving patients and survival time were 48 ± 3 and 51 ± 7 months, respectively (median ± SE). In the univariate analysis, 13 was the most powerful adverse prognostic factor for all times to event, especially for the survival time (P < .0001) and was followed by 2-microglobulin (2m) levels 2.5 mg/L or higher (P = .0001). The comparison of survival prognostic models including 2m 2.5 mg/L or greater and another factor favored the 13/2m combination. In 22 patients (20%) with no unfavorable factor, the median survival time was not reached at 111 months. In contrast, among 55 patients (50%) with one unfavorable factor and 33 patients (30%) with 2 unfavorable factors, median survival times were 47.3 ± 4.6 months and 25.3 ± 3.2 months, respectively (P < .0001). We conclude that 13, adequately detected by FISH analysis, is a very strong factor related to poor survival, especially when associated with a 2m level of 2.5 mg/L or higher. Routine FISH 13 assessment is strongly recommended for patients considered for HDT. (Blood. 2001;97:1566-1571) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Patients, materials, and... Results Discussion References Currently, an increasing number of patients with myeloma are referred for high-dose therapy (HDT), usually 1 or 2 courses of HDT with an autologous peripheral blood stem cell (PBSC) support.1 A careful prognostic evaluation of these patients is warranted to identify patients who maximally benefit from HDT as well as those who fail current HDT and are candidates for more innovative treatments. Up to now the best single and routinely performed prognostic factor remains serum 2 microglobulin (2m). Its powerful prognostic significance has been recognized in many studies over the last 15 years2-6 and confirmed in patients receiving HDT.7-11 Recently, abnormalities of chromosome 13 (monosomy and/or deletions, 13) have been associated with a short response duration and survival.12-15 In 2 studies, 13 had been detected using conventional cytogenetics (CC), which is hampered by the low mitotic activity of myelomatous plasma cells.12,13 Strong evidence now indicates that CC fails to recognize about one half of 13 as compared to fluorescence in situ hybridization (FISH), with incidences of 15% to 20% and almost 40%, respectively.12-17 Recently, 2 studies have used FISH to detect 13 and have demonstrated its adverse prognostic value, but these patients had received conventional chemotherapy.14,15 This study was designed to reevaluate the prognostic value of 13 detected by the FISH technique and to attempt to define a new prognostic staging for patients referred for HDT.     Patients, materials, and methods Top Abstract Introduction Patients, materials, and... Results Discussion References Patients The study included 110 patients with multiple myeloma diagnosed in the centers of Lille (85 patients) and Nantes (25 patients) between May 1990 and September 1998. All patients received an intensive treatment according to IFM protocols (mainly IFM 94 and 95), following 4 to 5 cycles of VAD chemotherapy (vincristine, Adriamycin, dexamethasone). The median time from diagnosis to HDT was 5.2 months. Total body irradiation was used in the conditioning regimen in 57 patients. The types of stem cells were bone marrow in 26 patients, PBSCs in 74 patients (2 patients with CD34 selection), PBSCs and bone marrow in 5 patients, and no stem cell support in 5 patients (high-dose melphalan 140 mg/m2 alone). All patients were evaluable for response. The patient and treatment characteristics are given in Table 1.                                View this table: [in this window] [in a new window]   Table 1. Patient and treatment characteristics (n = 110, except where indicated) Cytogenetic studies Conventional cytogenetics and FISH were performed as previously described.16,18,19 For FISH, we used a D13S319-specific probe, purchased from Vysis (Voisin-le-Bretonneux, France) according to the manufacturer's instructions. This probe maps to the 13q14 region, in the common deleted region observed in B-cell chronic lymphocytic leukemia (B-CLL). For 44 patients, the analysis was performed on highly purified plasma cells from fresh bone marrow collected at diagnosis. For 66 patients, the analysis was performed on frozen cytospin slides of bone marrow collected at diagnosis. All samples were collected before treatment and 100 cells were analyzed in both techniques. For the 44 patients with purified plasma cells from fresh bone marrow, the cells were fixed, after thawing, in methanol/acetic acid (3:1, v/v) for 30 minutes and air dried. After hybridization with the D13S319 probe and wash, cells were counterstained with DAPI in antifade, and examined using an epifluorescence microscope (Axioplan 2, Zeiss, Iena, Germany) equipped with a charged couple device camera and appropriate filters. According to previous studies, 13 was defined by the presence of only one fluorescent signal in at least 6% of plasma cells.16 However, in this series, the lowest percentage of plasma cells exhibiting only one signal was 72%. For the 66 patients with unselected cells, but with frozen cytospin slides, we used the D13S319-specific probe in a FISH method corresponding to interphase FISH coupled to immunologic revelation of the plasma cells. Briefly, after fixation in methanol/acetic acid (v/v), slides were incubated with fluorescein isothiocyanate (FITC)-labeled polyclonal antihuman light chains (final dilution, 1:100), as previously described.19 Afterward, the probe was layered on the slides (overnight hybridization). After washes, slides were counterstained with DAPI and were examined under a fluorescence microscope (DMRXA Leica, Wetzlar, Germany) using specific filters. Bone marrow samples from 8 healthy donors (bone marrow donors) were used as controls and were studied in the same conditions as those applied for the multiple myeloma patients (with the exception of immunostaining). The number of cells demonstrating one spot never exceeded 8% and, using mean plus 2 SDs, monosomy was ascertained when over 15% cells exhibited one red signal. However, in this study, all patients had at least 30% plasma cells with one red signal. Statistical analysis The following initial parameters were examined for their prognostic value on survival and progression: age, sex, stage (Durie and Salmon), substage, bone marrow plasmacytosis, M-component isotype, type of light chain, creatinine, 2m, lactate dehydrogenase (LDH), C-reactive protein (CRP), hemoglobin, leukocytes, platelets, calcium, albumin serum level, CC, and 13 FISH analysis. The distributions of each variable were compared between patients with 13 and those without through chi-square method or Wilcoxon test.20 Curves for progression-free survival (PFS), proportion of patients still in remission, survival after progression, and overall survival (OS) were calculated from diagnosis as time to event (death without progression or progression, progression, death after progression, death, respectively) using the Kaplan-Meier method21 and compared using the log-rank test.22 The estimate of the relative risk (RR) of event and its 95% confidence interval (95% CI) were estimated through the proportional hazard model.23 In these prognostic analyses, continuous variables were categorized in the following way. Each variable was first divided into 3 categories at approximately the 33rd and 67th percentiles. If the relative event rates24 (observed number of events divided by the expected number of events in a category, assuming no variation of event rate across categories) and the median times to event in 2 adjacent categories were not substantially different, these categories were grouped together.25 If no clear patterns were observed, the median and usual limits (as 2.5, 3, 4, and 6 mg/L for 2m) were taken as cut points. As a consequence, 2 to 3 categories were used for each continuous variable. Then, the ability of each parameter to increase predictive ability of the 2m in overall survival was tested through backward stepwise proportional hazard model23 including as prognostic factors 2m, the other tested parameter, and their interaction. Quality of the subsequent statistically significant models were classified according to the decrease in 2 log (likelihood) when compared to the model with no covariates, a decrease which is approximately distributed as a chi-square in which degrees of freedom correspond to the number of factors present in the model,26 the greater corresponding to the best fit for a fixed number of degrees of freedom. The same procedure was used to improve the prediction of the model including 2m and 13. No further improvements were looked for according to the number of deaths in our sample. The best prognostic models derived with 2 or 3 parameters were simplified by using the same procedure as the one described for univariate analysis leading to final models with 3 or 4 categories, only according to the number of unfavorable factors. The comparison of these final models with previously published models was performed by using Kaplan-Meier estimates of survival curves and quantified through the decrease in 2 log (likelihood), calculated on the same sample as explained above. All analyses were performed with SPSS software.27     Results Top Abstract Introduction Patients, materials, and... Results Discussion References After a median follow-up time of 48 ± 3 months among surviving patients, 79 progressions and 53 deaths, all after progression except one, were observed. The median PFS time, time to progression, survival after progression, and OS time for the whole series were 25 ± 2, 25 ± 2, 12 ± 3, and 51 ± 7 months, respectively. Response to treatment was no response (< 20% decrease of the M-component) in 22 patients (20%), minor response (20%-49% decrease of the M-component) in 10 patients (9%), partial response (50%-90% decrease of the M-component) in 22 patients (20%), very good partial response (> 90% decrease of the M-component) in 33 patients (30%), and complete response (absence of the paraprotein on immunofixation and  5% plasma cells in the bone marrow) in 23 patients (21%). 13 was found in 42 patients (38%). In addition to the chromosome 13 FISH analysis, 68 patients had bone marrow collected for CC. These patients consisted of the majority of patients from Lille (no CC was performed in Nantes). This cytogenetic analysis was unsuccessful in 8 patients (12%) and 60 patients had assessable metaphases. Conventional karyotype was abnormal in 29 patients and 16 of these 29 patients had 13 (results of CC and FISH analysis were concordant for these patients). In these latter patients, additional abnormalities besides those of chromosome 13 were investigated. The number of chromosomes was less than 46 in 7 patients, equal to 46 in 4 patients, and more than 46 in 5 patients. Structural abnormalities of chromosome 14 were frequent: add (14)(q32) to 6 patients and t(11;14)(q13;q32) to 3 patients. Deletion 6q was observed in 2 patients and deletion 16q in 2 patients (1 patient had nullosomy 16 and the other had der16 t(1;16)(p22;q11)). A significant positive association was found between 13 and female sex; 13 was observed in 59% of female patients versus 28% of male patients (P = .008). It was also the case for 13 and light-chain myeloma; 13 was present in 64% of patients with light-chain myeloma versus 34% of patients with another isotype (P = .030). Furthermore, 13 myelomas tended to have a higher stage (13 = 4 of 6 patients with primary plasma cell leukemia, 44% of stage III patients, and 25% of stage I/II patients; P = .054). When comparing mean levels (mean ± SE) of continuous items in patients with 13 versus in patients without 13, patients with 13 had a higher LDH serum level (302 ± 160 versus 255 ± 295 UI/L; P = .037), a lower hemoglobin level (10.1 ± 2.0 versus 11.3 ± 1.6 g/dL; P = .002), older age (56 ± 6 versus 52 ± 8 years; P = .030), and tended to have a higher 2m level (5.8 ± 5.1 versus 4.0 ± 2.6 mg/L; P = .092). Nevertheless, some patients had 13 despite low 2m; 9 (21% of patients with 13) and 15 patients (36%) had 13 and a serum 2m level below 2.5 and 3.0 mg/L, respectively. In the univariate analysis, the parameters significantly affecting PFS, survival after progression, and OS are presented in Table 2. 13 was the most powerful adverse prognostic factor for all times to event. Median survival times for patients with and without 13 were 27 ± 4 and 65 ± 10 months, respectively (P < .0001). Median PFS times for patients with and without 13 were 17 ± 2 and 33 ± 4 months, respectively (P = .0005) (Figures 1A and 2A). The response to the initial cytoreductive therapy (VAD) was not related to OS and PFS (P = .15 and P = .30, respectively) nor the type of bone marrow (fresh versus frozen) for FISH 13 analysis (P = .204 and P = .935, respectively). In our sample, which included 14 patients with stage I disease who received HDT according to IFM group criteria, no differences in OS and PFS could be seen between stage I and stage II patients. Concerning the 23 patients who reached a complete remission, their median complete remission duration was 28.1 ± 2.8 months (13 patients with progression). No factors reached statistical significance for complete remission duration although 13 (P = .094, RR = 2.5) and 2m 2.5 mg/L or greater (P = .094, RR = 3.4) had a borderline significance.                                View this table: [in this window] [in a new window]   Table 2. Prognostic factors at diagnosis, univariate analysis View larger version (24K): [in this window] [in a new window]   Figure 1. Overall survival according to the number of unfavorable factors. (A) Chromosome 13 deletions (13). (B) 13, 2m  2.5 mg/L. (C) 2m  2.5 mg/L, isotype IgA associated to 2m  2.5 mg/L. (D) 13, 2m  2.5 mg/L, isotype IgA associated to 2m  2.5 mg/L. O/N indicates number of deaths per number of patients. P < .0001 in all panels. In the multivariate analysis the comparison of OS prognostic models including 2m 2.5 mg/L or greater, another factor, and their interaction is presented in Table 3. In this approach, the decrease in 2 ×logarithm (likelihood) makes the comparison possible between various prognostic models through a unique criterion distributed as a chi-square. The comparison favored the combination of 2m and 13 (Figure 1B) preceding the combination of 2m and IgA isotype, when associated to 2m (Figure 1C). All other combinations were clearly inferior, including the 2m/CRP combination. Different cut-off values for 2m were tested for the 2m/13 model (3, 3.5, 4, and 6 mg/L) and the 2.5 mg/L level was found to be the best cut-off value (data not shown). Patients with no unfavorable factor (low-risk group), 2m less than 2.5 mg/L, absence of 13 represented 20% of the population (22 of 110) and had a median survival time more than 111 months (2 deaths among 22 patients). Patients with one unfavorable factor (intermediate-risk group), 50% of the population (55 of 110), had a median survival time of 47.3 ± 4.6 months (29 deaths among 55 patients; RR of death 9.8; 95% CI, 2.3-42.0). These patients consisted of 46 patients with 2m 2.5 mg/L or greater and lacking 13 and 9 patients with 2m less than 2.5 mg/L and 13. At the time of this report and taking into account the low number of patients with 2m less than 2.5 mg/L and 13, the OS curves of these 46 and 9 patients seem comparable and similar to that of the entire group (55 patients) (data not shown). Patients with 13 and 2m 2.5 mg/L or greater (high-risk group) represented 30% of the whole population and had a median survival time of 25.3 ± 3.2 months (22 deaths among 33 patients; RR of death 27.9; 95% CI, 6.3-124; P < .0001). These latter patients had a median PFS time of 15.2 ± 2.0 months. The results of the 2m/13 model regarding OS and PFS are shown in Figures 1B and 2B. Among the subgroup of 68 patients who had bone marrow collected for CC, we compared the use of FISH and CC. Eight patients were unclassified using CC, whereas they were evaluable using FISH; 7 patients belonged to the intermediate-risk group (6 progressions, 3 deaths); and 1 patient belonged to the high-risk group (rapid progression and death). In addition, 7 patients with an apparent normal karyotype using CC had 13 using FISH. Three patients (3 progressions, 2 deaths) would have been classified in the intermediate-risk group using CC, whereas they belonged to the high-risk group using FISH. The 4 other patients (3 progressions, 2 deaths) switched from the low-risk to the intermediate-risk group using FISH.                                View this table: [in this window] [in a new window]   Table 3. Comparison of prognostic models including 2m  2.5 mg/L and another factor* View larger version (18K): [in this window] [in a new window]   Figure 2. Progression-free survival according to the number of unfavorable factors. (A) Chromosome 13 deletions (13). (B) 13, 2m  2.5 mg/L. O/N indicates number of progressions and deaths without progression, per number of patients. P = .0005 in panel A and P < .0001 in panel B. Although inferior to the 2m/13 results, the results of the 2m/IgA isotype model were interesting and are shown in Figure 1C regarding OS. Furthermore, the following step of the multivariate analysis demonstrated that the OS prediction of the 2m/13 model was strengthened by the addition of the IgA isotype to the model, considering the 3 following parameters: 2m 2.5 mg/L or greater, 13, IgA isotype associated to 2m 2.5 mg/L or greater (Figure 1D). Patients without any adverse factor had a median survival time more than 111 months (2 deaths among 22 patients). Patients with 1 or 2 factors had median survival times of 52.3 ± 7.2 and 31.5 ± 4.3 months, respectively (RR of death 8.9; 95% CI, 2.1-38.7 and 23.5; 95% CI, 5.2-106, respectively). This stratification seemed particularly useful to isolate a small subgroup of 8 patients with 13, 2m 2.5 mg/L or greater and IgA isotype who had a very poor prognosis; these patients had a median PFS time of 7.8 ± 0.6 months (RR of death without progression or progression 16.1; 95% CI, 6.0-43.3) and a median OS time of 11.7 ± 2.3 months (8 of 8 deaths; RR of death 156; 95% CI, 30-841) (Figure 1D). We finally compared our 2 models, 13/2m and 2m/13/IgA, with a previously published prognostic model28 and a proposed adaptation of this model. We considered 2 2m/CRP models: 2m 2.5 mg/L/CRP or greater 6.0 mg/L or greater and 2m 6.0 mg/L/CRP or greater 6.0 mg/L or greater. These comparisons were done on a group of 102 patients (the whole sample except nonexcreting multiple myeloma and patients with CRP missing), and models including 13 appeared clearly superior. The decrease in 2 log (likelihood) was 52.695 and 35.614 for the 13/2m/IgA and the 13/2m models, respectively, but only 21.476 for 2m 2.5 mg/L/CRP, 6.0 mg/L or greater, and 14.391 for 2m 6.0 mg/L /CRP, 6.0 mg/L or greater.     Discussion Top Abstract Introduction Patients, materials, and... Results Discussion References This study emphasizes the pejorative role of FISH 13 on overall survival, especially in combination with a high serum 2m level. The studied sample was composed of 44 patients diagnosed between January and September 1998, representing the patients of both centers subsequently treated by HDT, patients for whom FISH 13 analysis was performed on fresh bone marrow. The other 66 patients were a subsample of the patients diagnosed between May 1990 and December 1997 and then treated by HDT in the Lille center (20-30 patients per year), for whom frozen cytospin slides performed at diagnosis were still available in 1998 when the laboratory in Nantes started routine FISH 13 analysis. Therefore, the selection bias was very unlikely. Indeed, no differences could be demonstrated between those 2 groups of patients in overall survival (P = .204) or PFS (P = .935). No differences could be demonstrated between the survival of the 2 groups among patients with a good, intermediate, or poor prognosis (defined by zero, one, or 2 adverse prognostic factors, 2m and 13). Similarly, differences between the 2 subsamples were limited to the date of diagnosis, age (mean 3 years higher in patients diagnosed in 1998), bone marrow plasmacytosis, and albumin level (mean 12% and 3 g/L higher in the same group). Chromosome 13 abnormalities were analyzed using a commercial probe mapping at 13q14, containing the D13S319 locus. This locus appears to be included in the most frequently deleted region as defined in the recent study of Shaughnessy and coworkers.29 Nevertheless, there is now evidence that marginal differences may occur with the use of different probes. In future studies it would probably be of interest to use more than one probe and carefully study, in a large group of patients, the clinical outcome with respect to different sites of deletion. Recently Barlogie and colleagues have recognized 13 as a highly unfavorable prognostic factor for event-free survival, OS, and complete response duration, but the study was plagued by the use of CC and the incidence of 13 was only 16%.13 FISH techniques are far more efficient than CC to identify numerical chromosomal abnormalities in myeloma30-32 and indeed we observed a 38% incidence of 13. This incidence was comparable to that found in the recent FISH study reported by Perez-Simon and colleagues involving 63 patients who received a standard treatment (33%) and allows a more precise evaluation of 13 prognostic value.17 In our study the superiority of FISH over CC was established in the subgroup of 68 patients who had both analyses. In our hands, the presence of 13 was critically important for all times to event, especially PFS and OS; patients lacking 13 had a median survival of approximately 65 months compared to 27 months for patients with 13 (P < .0001). Nevertheless, patients with 13 tend to achieve complete remission more frequently, possibly reflecting more pronounced proliferative features, higher sensitivity to HDT, but rapid relapse. To a certain extent, the role of prognostic factors appeared to vary with the time to event considered. Whereas 13 and 2m were related to all times to event studied, the type of light chain, age, CRP, and creatinine were mainly related to survival and plasmacytosis to progression. Similarly, the IgA isotype was more related to survival and IgG to progression (Table 2). Such results could explain some variations observed in prognostic factors from one study to another, due to particularities of the corresponding sample. Only a suggestive correlation was found between 13 and 2m serum level, which was so far the best reported prognostic factor in myeloma.2-6 Nine of 31 patients (29%) with 2m serum level below 2.5 mg/L had 13. These patients had a survival time clearly inferior to that of good-risk patients with low 2m and no 13. They would have been wrongly classified as good-risk patients in the absence of 13 FISH analysis, illustrating further the strong contribution of this latter analysis to the prognostic classification. In this study the multivariate analysis for OS prognosis was performed with the use at the first step of 2m (Table 3) and not 13, which was the most significant factor in the univariate analysis. We did that to determine the contribution on survival of factors in addition to the 2m level, so far the best prognostic factor. Nevertheless, when using classical stepwise approach, 13 was introduced at the first step and 2m at the second step, leading to the same bivariate model as the one presented in Table 3. In any case the IgA isotype was selected at the third step. Overall, whatever the method used, the 3 significant factors in the multivariate analysis were 13, 2m, and IgA isotype. We agree that in the latter model the highly pejorative group consisted of a small number of patients (8 patients) and this result would have to be confirmed in another sample. Nevertheless, this model with 4 prognostic categories defined by 2m, 13, and IgA isotype was highly significant when compared to the model with 3 prognostic categories defined by 13 and 2m level, and the survival time of this subgroup was actually very short with a median OS time of approximately 12 months. Concerning the main end-point, OS, besides the effect of 2m alone, several interesting interrelationships have been published, which permitted the stratification into clinically useful categories. In particular, the stratifications according to 2m and serum albumin,33 2m and CRP,28 and 2m and plasma cell labeling index34 have been found pertinent. In this study, the 13/2m model was far superior to 2m/CRP models. The addition of serum albumin, at the cut-off value of 35 g/L, did not improve the model containing 2m (the cut-off value of 30 g/L could not be used, because only 6 patients had a lower serum level). The plasma cell labeling index was not available in the vast majority of our patients and therefore this model could not be considered. In contrast, a good stratification was achieved using 2m and IgA. The adverse prognostic value of the IgA isotype in the HDT setting has already been pointed out.9 The 2m/IgA model was less powerful than the 13/2m model (Table 3). Good-risk patients had a slightly inferior survival and the high-risk group consisted of only 14 patients (13%), whereas there were 33 (30%) in the 13/2m model (Figure 1B,C). Nevertheless, the 2m/IgA model appeared as a valid alternative to the 13/2m model for investigators lacking cytogenetics. We conclude that 13, adequately detected by FISH analysis, is a very strong factor related to poor PFS and OS, especially when associated with 2m 2.5mg/L or greater. Although we have no real explanations concerning the mechanism by which 13 results in such an adverse prognosis, we strongly recommend routine FISH 13 assessment for patients considered for HDT. More needs to be done to improve HDT, especially for patients with 13 and high 2m who unequivocally fail current HDT, including tandem autotransplants. For these patients, our group has decided to evaluate a new tandem transplant program, using melphalan 200 mg/m2 with the first HDT cycle and, depending on age and availability of an HLA-identical sibling, melphalan 220 mg/m2 and a monoclonal anti-interleukin 6 antibody, with a second autotransplant or a nonmyeloablative allogeneic stem cell transplantation (for patients < 60 years old with an HLA-identical sibling). Thalidomide, which has recently demonstrated a strong antitumor activity in refractory myeloma,35 also deserves a complete and urgent evaluation.     Acknowledgments We would like to thank Colette Geneix, Jacqueline Regnault, and Myriam Cambié for their excellent technical assistance.     Footnotes Submitted December 14, 1999; accepted October 27, 2000. Supported in part by the Foundation contre la Leucémie, the Comité Départemental de Loire-Atlantique de la Ligue contre le Cancer, and the CHRU Lille. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, 59037 Lille Cédex, France; e-mail: t-facon{at}chru-lille.fr.     References Top Abstract Introduction Patients, materials, and... Results Discussion References 1. Attal M, Harousseau JL, Stoppa A, et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91-97[Abstract/Free Full Text]. 2. Bataille R, Durie BG, Grenier J. Serum 2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983;55:439-444[Medline] [Order article via Infotrieve]. 3. Bataille R, Grenier J, Sany J. 2-Microglobulin in myeloma: optimal use for staging, prognosis, and treatment: a prospective study of 160 patients. Blood. 1984;63:468-476[Abstract/Free Full Text]. 4. Brenning G, Simonsson B, Kallander C, Ahre A. Pretreatment serum 2-microglobulin in multiple myeloma. Br J Haematol. 1986;62:85-93[Medline] [Order article via Infotrieve]. 5. Durie BG, Stock-Novack D, Salmon SE, et al. Prognostic value of pretreatment serum 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990;75:823-830[Abstract/Free Full Text]. 6. Garenwal H, Durie BGM, Kyle RA, Finley P, Bower P, Serokmann R. Serum 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol. 1984;2:51-58[Abstract]. 7. Jagannath S, Barlogie B, Dicke K, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood. 1990;76:1860-1866[Abstract/Free Full Text]. 8. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood. 1995;86:4250-4256[Abstract/Free Full Text]. 9. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? Blood. 1996;88:838-847[Abstract/Free Full Text]. 10. Tricot G, Sawyer JR, Jagannath S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol. 1997;15:2659-2666[Abstract/Free Full Text]. 11. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65[Abstract/Free Full Text]. 12. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998;101:189-195[CrossRef][Medline] [Order article via Infotrieve]. 13. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010[Abstract/Free Full Text]. 14. Königsberg R, Zojer N, Ackermann J, et al. Predictive value of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol. 2000;18:804-812[Abstract/Free Full Text]. 15. Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925-1930[Abstract/Free Full Text]. 16. Avet-Loiseau H, Li JY, Morineau N, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood. 1999;94:2583-2589[Abstract/Free Full Text]. 17. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood. 1998;91:3366-3371[Abstract/Free Full Text]. 18. Laï JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85:2490-2497[Abstract/Free Full Text]. 19. Zandecki M, Obein V, Bernardi F, et al. Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol. 1995;90:693-696[Medline] [Order article via Infotrieve]. 20. Siegel S. Non parametric statistics for the behavioral sciences. New York, NY: MacGraw Hill; 1956:202. 21. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481[CrossRef]. 22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170[Medline] [Order article via Infotrieve]. 23. Cox DR. Regression models and life-tables. J R Statist Soc. 1972;B34:187. 24. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient; II, analysis and examples. Br J Cancer. 1977;35:1-39[Medline] [Order article via Infotrieve]. 25. Byar DP. Identification of prognostic factors. In: Buyse ME,Staquet MJ,Sylverster RJ, eds. Cancer clinical trials methods and practice. Oxford, England: Oxford Medical Publications; 1988:423. 26. Cox DR, Oakes D. Analysis of survival data. London, England: Chapman & Hall; 1984:91. 27. SPSS/PC+: Statistical package for social science, user's guide. Chicago, IL: SPSS; 1986. 28. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 1992;80:733-737[Abstract/Free Full Text]. 29. Shaughnessy J, Tian E, Sawyer J, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood. 2000;96:1505-1511[Abstract/Free Full Text]. 30. Flactif M, Zandecki M, Laï JL, et al. Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia. 1995;9:2109-2114[Medline] [Order article via Infotrieve]. 31. Drach J, Schuster J, Nowotny H, et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res. 1995;55:3854-3859[Abstract/Free Full Text]. 32. Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94:217-227[CrossRef][Medline] [Order article via Infotrieve]. 33. Durie BGM. Staging and kinetics of multiple myeloma. In: Wiernik PH,Canellos GP,Kyle RA,Schiffer CA, eds. Neoplastic diseases of the blood. 2nd ed. New York, NY: Churchill Livingstone; 1991:439. 34. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81:3382-3387[Abstract/Free Full Text]. 35. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1571[Abstract/Free Full Text]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al. Prognostic Significance of Copy-Number Alterations in Multiple Myeloma J. Clin. Oncol., September 20, 2009; 27(27): 4585 - 4590. [Abstract] [Full Text] [PDF] V. J. Louw, H. Louw, M. J. Webb, J.-L. Harousseau, and P. Moreau Autologous Stem-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., September 10, 2009; 361(11): 1118 - 1119. [Full Text] [PDF] K. Hanlon, S. Ellard, C. E. Rudin, S. Thorne, T. Davies, and L. W. Harries Evaluation of 13q14 Status in Patients with Chronic Lymphocytic Leukemia Using Single Nucleotide Polymorphism-Based Techniques J. Mol. Diagn., July 1, 2009; 11(4): 298 - 305. [Abstract] [Full Text] [PDF] S. Knop, C. Gerecke, P. Liebisch, M. S. Topp, U. Platzbecker, O. Sezer, C. Vollmuth, K. Falk, A. Glasmacher, U. Maeder, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood, April 30, 2009; 113(18): 4137 - 4143. [Abstract] [Full Text] [PDF] A. H. Bryce, R. P. Ketterling, M. A. Gertz, M. Lacy, R. A. Knudson, S. Zeldenrust, S. Kumar, S. Hayman, F. Buadi, R. A. Kyle, et al. Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis Haematologica, March 1, 2009; 94(3): 380 - 386. [Abstract] [Full Text] [PDF] M.-V. Mateos, J. M. Hernandez, M. T. Hernandez, N. C. Gutierrez, L. Palomera, M. Fuertes, P. Garcia-Sanchez, J. J. Lahuerta, J. de la Rubia, M.-J. Terol, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression Haematologica, April 1, 2008; 93(4): 560 - 565. [Abstract] [Full Text] [PDF] N. C. Munshi Investigative Tools for Diagnosis and Management Hematology, January 1, 2008; 2008(1): 298 - 305. [Abstract] [Full Text] [PDF] R. Manochakian, K. C. Miller, and A. A. Chanan-Khan Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma Oncologist, August 1, 2007; 12(8): 978 - 990. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, M. Attal, P. Moreau, C. Charbonnel, F. Garban, C. Hulin, S. Leyvraz, M. Michallet, I. Yakoub-Agha, L. Garderet, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome Blood, April 15, 2007; 109(8): 3489 - 3495. [Abstract] [Full Text] [PDF] A. Dispenzieri, S. V. Rajkumar, M. A. Gertz, M. Q. Lacy, R. A. Kyle, P. R. Greipp, T. E. Witzig, J. A. Lust, S. J. Russell, S. R. Hayman, et al. Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement Mayo Clin. Proc., March 1, 2007; 82(3): 323 - 341. [Abstract] [Full Text] [PDF] R. Fonseca Strategies for Risk-Adapted Therapy in Myeloma Hematology, January 1, 2007; 2007(1): 304 - 310. [Abstract] [Full Text] [PDF] P. G. Richardson, T. Hideshima, and K. C. Anderson Plasma cell dyscrasias ASH Self-Assessment Program, January 1, 2007; 2007(1): 298 - 327. [Full Text] [PDF] B. A. Walker, P. E. Leone, M. W. Jenner, C. Li, D. Gonzalez, D. C. Johnson, F. M. Ross, F. E. Davies, and G. J. Morgan Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma Blood, September 1, 2006; 108(5): 1733 - 1743. [Abstract] [Full Text] [PDF] F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Blood, May 1, 2006; 107(9): 3474 - 3480. [Abstract] [Full Text] [PDF] B. Barlogie, R. A. Kyle, K. C. Anderson, P. R. Greipp, H. M. Lazarus, D. D. Hurd, J. McCoy, S. R. Dakhil, K. S. Lanier, R. A. Chapman, et al. Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321 J. Clin. Oncol., February 20, 2006; 24(6): 929 - 936. [Abstract] [Full Text] [PDF] P. Moreau, C. Hullin, F. Garban, I. Yakoub-Agha, L. Benboubker, M. Attal, G. Marit, J.-G. Fuzibet, C. Doyen, L. Voillat, et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol Blood, January 1, 2006; 107(1): 397 - 403. [Abstract] [Full Text] [PDF] Z. Chen, B. Issa, S. Huang, E. Aston, J. Xu, M. Yu, A. R. Brothman, and M. Glenn A Practical Approach to the Detection of Prognostically Significant Genomic Aberrations in Multiple Myeloma J. Mol. Diagn., November 1, 2005; 7(5): 560 - 565. [Abstract] [Full Text] [PDF] P. G. G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, T. Hideshima, H. Xiao, D. Esseltine, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Blood, November 1, 2005; 106(9): 2977 - 2981. [Abstract] [Full Text] [PDF] X. Leleu, G. Le Friec, T. Facon, L. Amiot, R. Fauchet, B. Hennache, V. Coiteux, I. Yakoub-Agha, S. Dubucquoi, H. Avet-Loiseau, et al. Total Soluble HLA Class I and Soluble HLA-G in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Clin. Cancer Res., October 15, 2005; 11(20): 7297 - 7303. [Abstract] [Full Text] [PDF] S. V. Rajkumar and R. A. Kyle Multiple Myeloma: Diagnosis and Treatment Mayo Clin. Proc., October 1, 2005; 80(10): 1371 - 1382. [Abstract] [PDF] A. K. Stewart and R. Fonseca Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling J. Clin. Oncol., September 10, 2005; 23(26): 6339 - 6344. [Abstract] [Full Text] [PDF] S.-Y. Huang, M. Yao, J.-L. Tang, W. Tsay, F.-Y. Lee, M.-C. Liu, C.-H. Wang, Y.-C. Chen, M.-C. Shen, and H.-F. Tien Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan Ann. Onc., September 1, 2005; 16(9): 1530 - 1538. [Abstract] [Full Text] [PDF] H. Chang, C. Qi, Q.-L. Yi, D. Reece, and A. K. Stewart p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation Blood, January 1, 2005; 105(1): 358 - 360. [Abstract] [Full Text] [PDF] A. Palumbo, S. Bringhen, M. T. Petrucci, P. Musto, F. Rossini, M. Nunzi, V. M. Lauta, C. Bergonzi, A. Barbui, T. Caravita, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial Blood, November 15, 2004; 104(10): 3052 - 3057. [Abstract] [Full Text] [PDF] N. C. Gutierrez, J. L. Garcia, J. M. Hernandez, E. Lumbreras, M. Castellanos, A. Rasillo, G. Mateo, J. M. Hernandez, S. Perez, A. Orfao, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma Blood, November 1, 2004; 104(9): 2661 - 2666. [Abstract] [Full Text] [PDF] T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF] N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. A. Perez-Simon, J. F. San Miguel, M. Kiehl, A. Fauser, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation Blood, June 1, 2004; 103(11): 4056 - 4061. [Abstract] [Full Text] [PDF] N. Murashige, Y. Kishi, W. J. Chng, P. Musto, and M. Attal Tandem Bone Marrow Transplantation in Multiple Myeloma N. Engl. J. Med., April 1, 2004; 350(14): 1466 - 1467. [Full Text] [PDF] R. Fonseca, B. Barlogie, R. Bataille, C. Bastard, P. L. Bergsagel, M. Chesi, F. E. Davies, J. Drach, P. R. Greipp, I. R. Kirsch, et al. Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report Cancer Res., February 15, 2004; 64(4): 1546 - 1558. [Abstract] [Full Text] [PDF] J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson Multiple Myeloma Hematology, January 1, 2004; 2004(1): 237 - 256. [Abstract] [Full Text] [PDF] B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF] H. Kaufmann, J. Ackermann, H. Greinix, T. Nosslinger, H. Gisslinger, A. Keck, H. Ludwig, N. Worel, P. Kalhs, C. Zielinski, et al. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features Ann. Onc., November 1, 2003; 14(11): 1667 - 1672. [Abstract] [Full Text] [PDF] F. Magrangeas, V. Nasser, H. Avet-Loiseau, B. Loriod, O. Decaux, S. Granjeaud, F. Bertucci, D. Birnbaum, C. Nguyen, J.-L. Harousseau, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease Blood, June 15, 2003; 101(12): 4998 - 5006. [Abstract] [Full Text] [PDF] R. Fonseca, E. Blood, M. Rue, D. Harrington, M. M. Oken, R. A. Kyle, G. W. Dewald, B. Van Ness, S. A. Van Wier, K. J. Henderson, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood, June 1, 2003; 101(11): 4569 - 4575. [Abstract] [Full Text] [PDF] J. Shaughnessy, J. Jacobson, J. Sawyer, J. McCoy, A. Fassas, F. Zhan, K. Bumm, J. Epstein, E. Anaissie, S. Jagannath, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression Blood, May 15, 2003; 101(10): 3849 - 3856. [Abstract] [Full Text] [PDF] J. A. Child, G. J. Morgan, F. E. Davies, R. G. Owen, S. E. Bell, K. Hawkins, J. Brown, M. T. Drayson, P. J. Selby, and the Medical Research Council Adult Leukaemia Worki High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma N. Engl. J. Med., May 8, 2003; 348(19): 1875 - 1883. [Abstract] [Full Text] [PDF] C. M. Segeren, P. Sonneveld, B. van der Holt, E. Vellenga, A. J. Croockewit, G. E. G. Verhoef, J. J. Cornelissen, M. R. Schaafsma, M. H. J. van Oers, P. W. Wijermans, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study Blood, March 15, 2003; 101(6): 2144 - 2151. [Abstract] [Full Text] [PDF] P. L. Bergsagel Prognostic Factors in Multiple Myeloma: It's in the Genes Clin. Cancer Res., February 1, 2003; 9(2): 533 - 534. [Full Text] [PDF] L. Laterveer, L. F. Verdonck, T. Peeters, E. Borst, A. C. Bloem, and H. M. Lokhorst Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma Blood, February 1, 2003; 101(3): 1201 - 1201. [Full Text] [PDF] G Pratt Molecular aspects of multiple myeloma Mol. Pathol., October 1, 2002; 55(5): 273 - 283. [Abstract] [Full Text] [PDF] P. Moreau, T. Facon, X. Leleu, N. Morineau, P. Huyghe, J.-L. Harousseau, R. Bataille, and H. Avet-Loiseau Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy Blood, August 13, 2002; 100(5): 1579 - 1583. [Abstract] [Full Text] [PDF] D. Leroux, F. Mugneret, M. Callanan, I. Radford-Weiss, N. Dastugue, J. Feuillard, F. Le Mee, G. Plessis, P. Talmant, N. Gachard, et al. CD4+, CD56+ DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique Blood, May 13, 2002; 99(11): 4154 - 4159. [Abstract] [Full Text] [PDF] H. Avet-Loiseau, T. Facon, B. Grosbois, F. Magrangeas, M.-J. Rapp, J.-L. Harousseau, S. Minvielle, and R. Bataille Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation Blood, March 15, 2002; 99(6): 2185 - 2191. [Abstract] [Full Text] [PDF] F. Zhan, J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, R. Sanderson, Y. Yang, C. Wilson, M. Zangari, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells Blood, March 1, 2002; 99(5): 1745 - 1757. [Abstract] [Full Text] [PDF] R. Fonseca, D. Harrington, M. M. Oken, G. W. Dewald, R. J. Bailey, S. A. Van Wier, K. J. Henderson, E. A. Blood, S. V. Rajkumar, N. E. Kay, et al. Biological and Prognostic Significance of Interphase Fluorescence in Situ Hybridization Detection of Chromosome 13 Abnormalities ({Delta}13) in Multiple Myeloma: An Eastern Cooperative Oncology Group Study Cancer Res., February 1, 2002; 62(3): 715 - 720. [Abstract] [Full Text] [PDF] K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text] H. Avet-Loiseau, F. Gerson, F. Magrangeas, S. Minvielle, J.-L. Harousseau, and R. Bataille Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors Blood, November 15, 2001; 98(10): 3082 - 3086. [Abstract] [Full Text] [PDF] B. G. M. Durie Multiple Myeloma: What's New CA Cancer J Clin, September 1, 2001; 51(5): 271 - 272. [Full Text] [PDF] W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau Multiple Myeloma Hematology, January 1, 2001; 2001(1): 157 - 177. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Facon, T. Articles by Mary, J.-Y. Search for Related Content PubMed PubMed Citation Articles by Facon, T. Articles by Mary, J.-Y. Related Collections Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020